OPKO Health Reports Third Quarter Financial and Operating Results
Consolidated revenue increased to $298.0 million for the three months ended September 30, 2016 from $143.0 million for the comparable period of 2015. Consolidated revenue for the nine months ended September 30, 2016 increased to $946.2 million from $215.5 million for the comparable period of 2015.
Net loss was $15.0 million for the three months ended September 30, 2016 compared to net income of $128.2 million for the comparable period of 2015. For the nine months ended September 30, 2016, net loss was $11.4 million compared to net loss of $31.6 million for the comparable period of 2015
U.S. commercial launch of RAYALDEE® planned for late November 2016; full marketing and sales team now in place
Completed acquisition of Transition Therapeutics; Phase 2 clinical trial protocols for two important products being developed
4Kscore test utilization continues to grow; many payors now in place, negotiations with others continue
Topline data for three long acting biologic products to be presented
Long acting hGH-CTP topline Phase 3 data in adults in 4Q 2016
Long acting Factor VIIa-CTP safety data from the first in human Phase 2a trial in early 2017
Long acting oxyntomodulin first in human Phase 1 safety data expected early 2017
Clinical trials for Claros point of care (POC) PSA test to begin in late 2016; PMA filing anticipated in 1H 2017; Claros POC testosterone test clinical trials and 510(k) filing to follow in 2017
